Objective: To evaluate the efficacy and safety of
sparfloxacin for the treatmeat of acute bacterial infection. Methods:
A randomized controlled and open clinical trial was carried out. Ofloxacin was served as the controlled drug. The regimen for
sparfloxacin was 200mg intravenous qd or q12h, and ofloxacin was 200mg intravenous q12h for 5～14 days. Results: A total of 76 patients were enrolled in the study, 39 patients in trial group, 20 in control group and 17 in open group. Giant injection (GI) group: the
effective rate were 84.21%, 85.00% and 88.89% in trial, control and open group respectively; Minor injection (MI) group: the effective rate were 85.00%, 85.00% and 100.00%. The bacterial clearance rates were 92.86%, 87.50%, 100.00% in GI group and 80.00%, 87.50%, 100.00% in MI group respectively. The difference between the trial group and the control group was not statistically significant ( P >0.05). The adverse drug reaction rates were 15.00% (GI), 10.00% (MI) in trial group and 10.00% in control group. There were no statical differences ( P >0.05). In open group the adverse drug reaction rates were 0.00% (GI) and 12.50% (MI). Conclusion: Sparfloxacin for injection has broad antibacterial spectrum and potent antibacterial activity, and it is safe and effective in the treatment of moderate or severe bacterial infections.